Genmab A/S (GNMSF)
OTCMKTS
· Delayed Price · Currency is USD
188.80
-8.65 (-4.38%)
May 13, 2025, 9:55 AM EDT
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
$1,188,453
Profits / Employee
$430,991
Market Cap
12.03B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
CytoDyn | 9 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Genmab News
- 1 day ago - Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress - Business Wire
- 1 day ago - Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress - GlobeNewsWire
- 3 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 6 days ago - Genmab reports Q1 results - Seeking Alpha
- 7 days ago - Genmab Announces Financial Results for the First Quarter of 2024 - GlobeNewsWire
- 10 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 13 days ago - Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) - Business Wire
- 17 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire